Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Partners with Gilead on CLL Clinical Trials; Revises Expected Proceeds from IPO

NEW YORK (GenomeWeb News) – Cancer Genetics today announced that Gilead Sciences has selected it to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.

Separately, the Rutherford, NJ-based cancer diagnostic company again lowered the anticipated net proceeds from its planned initial public offering.

Its deal with Gilead covers both national and international clinical trials. Cancer Genetics will use its SelectOne program that includes genomic assays in CLL, data and logistics management, as well as CLIA- and CAP-accredited clinical laboratory testing.

It added that ongoing studies employ several methodologies such as flow cytometry, fluorescent in situ hybridization, and molecular assays, "including mutational analyses of IGHV, TP53, NOTCH1" and Cancer Genetics' MatBA-CLL/SLL, an array-CGH assay for mature B-cell neoplasm.

The company said it anticipates the trials to last several years "and may potentially enable an expedited and more efficient development timeline based on improved patient stratification."

Financial terms of the deal were not disclosed.

Also, late Monday, Cancer Genetics disclosed in an amended Form S-1 filed with the US Securities and Exchange Commission that it has revised its planned IPO. It now said that it plans to offer 1.65 million shares of its stock at a price of between $10 and $12 per share. At the midpoint price of $11 per share, the offering is expected to bring in net proceeds of about $14.3 million. If the offering's underwriters, Aegis Capital and Feltl & Co., exercise their over-allotment option in full, net proceeds would be about $16.8 million.

It is the second time in two weeks that the company has lowered the expected proceeds from its planned IPO. Last week, it said that it planned to offer 1.85 million shares of its stock for between $10 and $12 per share. At the $11 midpoint price, net proceeds would have been about $16.3 million, or $19.2 million if Aegis and Feltl &Co. exercised their over-allotment option in full.

Before that, Cancer Genetics had said that it expected to bring in net proceeds of as much as $23.5 million from its IPO. The company initially filed its registration statement for the IPO in December 2011, saying it hoped to raise $48.6 million in net proceeds.

If approved, Cancer Genetics' stock would list on Nasdaq under ticker symbol "CGIX".

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.